Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Oncology/NSCLC (advanced Non-Small Cell Lung Cancer)

NSCLC (advanced Non-Small Cell Lung Cancer)

8

Pipeline Programs↗

13

Active Trials↗

13

Companies Involved↗

NSCLC (Advanced Non-small Cell Lung Cancer) is an early-stage landscape with 8 programs across 13 companies. The most active players are ALX Oncology Inc., Multitude Therapeutics Inc., BlossomHill Therapeutics.

Intelligence

Pipeline Metrics

Competitive Density

41/100

Pipeline Velocity

32/100

Mech. Concentration

100/100

Completion Rate

0/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

ALX Oncology Inc.

1 program

Multitude Therapeutics Inc.

1 program

BlossomHill Therapeutics

1 program

Pipeline

Programs by Phase

Preclinical4

Nht102

Nob Hill Therapeutics, Inc.

BH-30643

BlossomHill Therapeutics

AMT-116

Multitude Therapeutics Inc.

NK Cells

Southwest Hospital, China

Phase 11

ALX2004

ALX Oncology Inc.

Phase 23

Ivonescimab

Summit Therapeutics

Sacituzumab Tirumotecan

Merck & Co.

Anlotinib

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

No programs

Approved

No programs

Analysis

Modality Breakdown

7programs

Small molecule457%

Monoclonal antibody114%

Antibody–drug conjugate114%

Cell therapy114%

Modality classified for 88% of 8 pipeline programs.

Analysis

Trial Status

14

clinical trials

Not yet recruiting6 · 43%

Recruiting4 · 29%

Active, not recruiting3 · 21%

Withdrawn1 · 7%

Clinical Trials

Trial Activity

14 trials

A Phase 1/2 Open-Label, Multicenter, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BH-30643 in Adult Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations (SOLARA)

Recruiting·BBlossomHill Therapeutics·Preclinical·NCT06706076·675 enrolled

Open-Label, Global, Multicenter, Randomized, Phase 2/3 Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy

Recruiting·MMultitude Therapeutics Inc.·Preclinical·NCT07718737·512 enrolled

A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants With Advanced or Metastatic Select Solid Tumors

Recruiting·AALX Oncology Inc.·Phase 1·NCT07085091·170 enrolled

A Phase III, Randomized, Multicentre, Open Label Study to Assess the Efficacy and Safety of Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients With EGFR PACC Mutation or EGFR l861q Mutation

Recruiting·AAllist Pharmaceuticals, Inc.·Phase 3·NCT06956001·300 enrolled

Efficiency of Contemporary Off-line Adaptive Radiotherapy for Lung Cancer

Active, not recruiting·UUniversitaire Ziekenhuizen KU Leuven·Preclinical·NCT07259447·30 enrolled

A Multicenter Clinical Study Evaluating the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Anlotinib as Second-Line Treatment for Patients With Driver Gene-Negative Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Active, not recruiting·NNanfang Hospital, Southern Medical University·Phase 2·NCT07703228·38 enrolled

A Phase II Clinical Trial of Ivonescimab Plus Third-generation EGFR-TKIs in Advanced Non-small Cell Lung Cancer With Gradual or Potential Progression After EGFR-TKIs Treatment

Active, not recruiting·SShandong Cancer Hospital and Institute·Phase 2·NCT07669051·36 enrolled

A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Continuous Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced/Metastatic Solid Tumors

Not yet recruiting·NNatera, Inc.·Preclinical·NCT07689812·920 enrolled

A Phase 1/2 Open-label, Multi-Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of NHT102 (5-Azacytidine Dry Powder Formulation Delivered by a Novel Inhalation Delivery System) in Patients With Advanced Non-Small Cell Lung Cancer

Not yet recruiting·NNob Hill Therapeutics, Inc.·Preclinical·NCT07864584·100 enrolled

A Randomized, Double-Blind, Multicenter, Phase II/III Study to Evaluate HLX37 (Recombinant Human Anti-PD-L1 and Anti-VEGF Bispecific Antibody) in Combination With Chemotherapy Versus Pembrolizumab in Combination With Chemotherapy for First-Line Therapy of Advanced Non-Small Cell Lung Cancer

Not yet recruiting· Shanghai Henlius Biotech logo

Shanghai Henlius Biotech·Preclinical·NCT07865910·1,438 enrolled

A Randomized, Open-Label, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of JYP0322 Versus Crizotinib in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Not yet recruiting·GGuangzhou JOYO Pharma Co., Ltd·Phase 3·NCT07816380·216 enrolled

An Exploratory Clinical Study to Evaluate the Safety and Efficacy of Allogeneic NK Cell Injection Combined With Standard Maintenance Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors

Not yet recruiting·BBOE Technology Group Co., Ltd.·Preclinical·NCT07551778·42 enrolled

An Open-label, Multicenter Phase II Clinical Trial to Evaluate ALK201 for Injection Combined With Ivonescimab Injection in Subjects With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

Not yet recruiting·SShanghai Allink Biotherapeutics Co., Ltd.·Phase 2·NCT07742956·156 enrolled

Phase 3, Randomized, Open-Label Study of Nogapendekin Alfa Inbakicept in Combination With Standard of Care Versus Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

Withdrawn·IImmunityBio, Inc.·Phase 3·NCT07524257

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)